REFERENCES
1. Kließ M, Martins R, Connolly MP. Major cost drivers in assessing the economic burden of Alzheimer’s disease: a structured, rapid review. J Prev Alzheimers Dis. 2021;8:362-70.
2. GBD 2016 Dementia Collaborators. Global, regional, and national burden of Alzheimer’s disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18:88-106.
3. Mielke MM, Aggarwal NT, Vila-Castelar C, et al; Diversity and Disparity Professional Interest Area Sex and Gender Special Interest Group. Consideration of sex and gender in Alzheimer’s disease and related disorders from a global perspective. Alzheimers Dement 2022;18:2707-24.
4. Eikelboom WS, Pan M, Ossenkoppele R, et al. Sex differences in neuropsychiatric symptoms in Alzheimer’s disease dementia: a meta-analysis. Alzheimers Res Ther. 2022;14:48.
5. Moore LD, Le T, Fan G. DNA methylation and its basic function. Neuropsychopharmacology. 2013;38:23-38.
6. McCartney DL, Zhang F, Hillary RF, et al. An epigenome-wide association study of sex-specific chronological ageing. Genome Med. 2019;12:1.
7. Yusipov I, Bacalini MG, Kalyakulina A, et al. Age-related DNA methylation changes are sex-specific: a comprehensive assessment. Aging. 2020;12:24057-80.
8. Yousefi P, Huen K, Davé V, Barcellos L, Eskenazi B, Holland N. Sex differences in DNA methylation assessed by 450 K BeadChip in newborns. BMC Genomics. 2015;16:911.
9. Singmann P, Shem-Tov D, Wahl S, et al. Characterization of whole-genome autosomal differences of DNA methylation between men and women. Epigenetics Chromatin. 2015;8:43.
10. Ye W, Siwko S, Tsai RYL. Sex and race-related DNA methylation changes in hepatocellular carcinoma. Int J Mol Sci. 2021;22:3820.
11. Xia Y, Dai R, Wang K, et al. Sex-differential DNA methylation and associated regulation networks in human brain implicated in the sex-biased risks of psychiatric disorders. Mol Psychiatry. 2021;26:835-48.
12. Zhang L, Young JI, Gomez L, et al. Sex-specific DNA methylation differences in Alzheimer’s disease pathology. Acta Neuropathol Commun. 2021;9:77.
13. Pellegrini C, Pirazzini C, Sala C, et al. A meta-analysis of brain DNA methylation across sex, age, and Alzheimer’s disease points for accelerated epigenetic aging in neurodegeneration. Front Aging Neurosci. 2021;13:639428.
14. Braun PR, Han S, Hing B, et al. Genome-wide DNA methylation comparison between live human brain and peripheral tissues within individuals. Transl Psychiatry. 2019;9:47.
15. Wei X, Zhang L, Zeng Y. DNA methylation in Alzheimer’s disease: In brain and peripheral blood. Mech Ageing Dev. 2020;191:111319.
16. Silva TC, Young JI, Zhang L, et al. Cross-tissue analysis of blood and brain epigenome-wide association studies in Alzheimer’s disease. Nat Commun. 2022;13:4852.
17. Silva TC, Zhang W, Young JI, et al. Distinct sex-specific DNA methylation differences in Alzheimer’s disease. Alzheimers Res Ther. 2022;14:133.
18. Nabais MF, Laws SM, Lin T, et al; Australian Imaging Biomarkers and Lifestyle study, Alzheimer’s Disease Neuroimaging Initiative. Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biol 2021;22:90.
19. Roubroeks JAY, Smith AR, Smith RG, et al. An epigenome-wide association study of Alzheimer’s disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiol Aging. 2020;95:26-45.
20. Li Y, Chen JA, Sears RL, et al. An epigenetic signature in peripheral blood associated with the haplotype on 17q21.31, a risk factor for neurodegenerative tauopathy. PLoS Genet. 2014;10:e1004211.
21. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology. 1984;34:939-44.
22. Morris TJ, Butcher LM, Feber A, et al. ChAMP: 450k chip analysis methylation pipeline. Bioinformatics. 2014;30:428-30.
23. Troyanskaya O, Cantor M, Sherlock G, et al. Missing value estimation methods for DNA microarrays. Bioinformatics. 2001;17:520-5.
24. Zhou W, Laird PW, Shen H. Comprehensive characterization, annotation and innovative use of Infinium DNA methylation BeadChip probes. Nucleic Acids Res. 2017;45:e22.
25. Chen YA, Lemire M, Choufani S, et al. Discovery of cross-reactive probes and polymorphic CpGs in the Illumina Infinium HumanMethylation450 microarray. Epigenetics. 2013;8:203-9.
26. Teschendorff AE, Marabita F, Lechner M, et al. A beta-mixture quantile normalization method for correcting probe design bias in Illumina Infinium 450 k DNA methylation data. Bioinformatics. 2013;29:189-96.
27. Turner SD. qqman: an R package for visualizing GWAS results using Q-Q and manhattan plots. J Open Source Softw. 2018;3:731.
28. Smyth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article3.
29. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc B. 1995;57:289-300.
30. Jaffe AE, Murakami P, Lee H, et al. Bump hunting to identify differentially methylated regions in epigenetic epidemiology studies. Int J Epidemiol. 2012;41:200-9.
31. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. Bioinformatics. 2010;26:2190-1.
32. Bu D, Luo H, Huo P, et al. KOBAS-i: intelligent prioritization and exploratory visualization of biological functions for gene enrichment analysis. Nucleic Acids Res. 2021;49:W317-25.
33. GSEA/MSigDB Team. GSEA FAQ. 2022. Available from: https://software.broadinstitute.org/cancer/software/gsea/wiki/index.php/FAQ#Why_does_GSEA_use_a_false_discovery_rate_.28FDR.29_of_0.25_rather_than_the_more_classic_0.05.3F. [Last accessed on 12 Dec 2024].
34. Xiong Z, Yang F, Li M, et al. EWAS Open Platform: integrated data, knowledge and toolkit for epigenome-wide association study. Nucleic Acids Res. 2022;50:D1004-9.
35. Zaghlool SB, Al-Shafai M, Al Muftah WA, Kumar P, Falchi M, Suhre K. Association of DNA methylation with age, gender, and smoking in an Arab population. Clin Epigenetics. 2015;7:6.
36. Rudolf R, Busch R, Patra AK, et al. Architecture and expression of the nfatc1 gene in lymphocytes. Front Immunol. 2014;5:21.
37. Hashimoto T, Wakabayashi T, Watanabe A, et al. CLAC: a novel Alzheimer amyloid plaque component derived from a transmembrane precursor, CLAC-P/collagen type XXV. EMBO J. 2002;21:1524-34.
38. Drummond E, Kavanagh T, Pires G, et al. The amyloid plaque proteome in early onset Alzheimer’s disease and Down syndrome. Acta Neuropathol Commun. 2022;10:53.
39. Tong Y, Xu Y, Scearce-Levie K, Ptácek LJ, Fu YH. COL25A1 triggers and promotes Alzheimer’s disease-like pathology in vivo. Neurogenetics. 2010;11:41-52.
40. Wheeler JM, McMillan P, Strovas TJ, et al. Activity of the poly(A) binding protein MSUT2 determines susceptibility to pathological tau in the mammalian brain. Sci Transl Med. 2019;11:eaao6545.
41. McMillan PJ, Strovas TJ, Baum M, et al. Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer’s disease. Acta Neuropathol Commun. 2021;9:117.
42. Tsiknia AA, Edland SD, Sundermann EE, et al; Alzheimer’s Disease Neuroimaging Initiative. Sex differences in plasma p-tau181 associations with Alzheimer’s disease biomarkers, cognitive decline, and clinical progression. Mol Psychiatry 2022;27:4314-22.
43. Walker RM, Bermingham ML, Vaher K, et al. Epigenome-wide analyses identify DNA methylation signatures of dementia risk. Alzheimers Dement. 2020;12:e12078.
44. Fransquet PD, Lacaze P, Saffery R, et al. Blood DNA methylation signatures to detect dementia prior to overt clinical symptoms. Alzheimers Dement. 2020;12:e12056.
45. Li QS, Vasanthakumar A, Davis JW, et al; Alzheimer’s Disease Neuroimaging Initiative (ADNI). Association of peripheral blood DNA methylation level with Alzheimer’s disease progression. Clin Epigenetics 2021;13:191.
46. Guo L, Zhong MB, Zhang L, Zhang B, Cai D. Sex differences in Alzheimer’s disease: insights from the multiomics landscape. Biol Psychiatry. 2022;91:61-71.
47. Hu RT, Yu Q, Zhou SD, et al. Co-expression network analysis reveals novel genes underlying Alzheimer’s disease pathogenesis. Front Aging Neurosci. 2020;12:605961.
48. Popovitchenko T, Park Y, Page NF, et al. Translational derepression of Elavl4 isoforms at their alternative 5’ UTRs determines neuronal development. Nat Commun. 2020;11:1674.
49. Bowles KR, Silva MC, Whitney K, et al. ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids. Cell. 2021;184:4547-63.e17.
50. Balschun D, Moechars D, Callaerts-Vegh Z, et al. Vesicular glutamate transporter VGLUT1 has a role in hippocampal long-term potentiation and spatial reversal learning. Cereb Cortex. 2010;20:684-93.
51. Du X, Li J, Li M, et al. Research progress on the role of type I vesicular glutamate transporter (VGLUT1) in nervous system diseases. Cell Biosci. 2020;10:26.
52. Zhou JW, Zhao M, Rang WL, et al. Proteome profiling identified amyloid-β protein precursor as a novel binding partner and modulator of VGLUT1. J Alzheimers Dis. 2021;81:981-1038.
53. Vargas LM, Cerpa W, Muñoz FJ, Zanlungo S, Alvarez AR. Amyloid-β oligomers synaptotoxicity: the emerging role of EphA4/c-Abl signaling in Alzheimer’s disease. Biochim Biophys Acta Mol Basis Dis. 2018;1864:1148-59.
54. Tamura K, Chiu YW, Shiohara A, Hori Y, Tomita T. EphA4 regulates Aβ production via BACE1 expression in neurons. FASEB J. 2020;34:16383-96.
55. Jun GR, You Y, Zhu C, et al; Alzheimer’s Disease Genetics Consortium. Protein phosphatase 2A and complement component 4 are linked to the protective effect of APOE ɛ2 for Alzheimer’s disease. Alzheimers Dement 2022;18:2042-54.
56. Wu KM, Zhang YR, Huang YY, Dong Q, Tan L, Yu JT. The role of the immune system in Alzheimer’s disease. Ageing Res Rev. 2021;70:101409.
57. Paranjpe MD, Belonwu S, Wang JK, et al. Sex-specific cross tissue meta-analysis identifies immune dysregulation in women with Alzheimer’s disease. Front Aging Neurosci. 2021;13:735611.
58. Manji Z, Rojas A, Wang W, Dingledine R, Varvel NH, Ganesh T. 5xFAD mice display sex-dependent inflammatory gene induction during the prodromal stage of Alzheimer’s disease. J Alzheimers Dis. 2019;70:1259-74.
59. Maunakea AK, Phankitnirundorn K, Peres R, et al. Socioeconomic status, lifestyle, and DNA methylation age among racially and ethnically diverse adults: NIMHD social epigenomics program. JAMA Netw Open. 2024;7:e2421889.
